we probe the fundamental structure of particles that make up everything around us We do so using the world's largest and most complex scientific instruments Know more The Higgs Boson The W boson The Z boson The Large Hadron Collider The Birth of the web Antimatter Latest news Media News The research programme at CERN covers topics from kaons to cosmic rays and from the Standard Model to supersymmetry See all resources The other circuits will remain inactive until further notice More Social Media Accounts James Welling is a photographer who lives in New York. He is a lecturer at Princeton University. Home A general view of the Large Hadron Collider (LHC) at the Organization for Nuclear Research (CERN) in Saint-Genis-Pouilly the 27-kilometer Large Hadron Collider (LHC) restarted on Friday after a break of more than three years for upgrading and maintenance work amid COVID-19 in hunt for "dark matter." Physicists hope the resumption of collisions will help in their quest for so-called "dark matter" that lies beyond the visible universe Dark matter is thought to be five times more prevalent than ordinary matter but does not absorb Searches have so far left scientists empty-handed "We are going to increase the number of collisions drastically and therefore the probability of new discoveries also," said Rende Steerenberg who is in charge of control room operations of LHC located under a Swiss-French border area near Geneva is perhaps best known for helping confirm the subatomic Higgs boson in 2012 The European Organization for Nuclear Research said that two beams of protons circulated in opposite directions around the accelerator on Friday high-energy collisions are still a couple of months away A first round of experiments took place from 2010 to 2012 "The machines and facilities underwent major upgrades during the second long shutdown of CERN's accelerator complex," CERN's director for accelerators and technology He added that the collider "will now operate at an even higher energy" and deliver significantly more data The hunt for dark matter: Scientists prepare CERN collider restart World's largest atom smasher holder intensifies measure against Russia Disinformation report hotline: 010-85061466 Please enable JS and disable any ad blocker The 2022 edition of the Fête de la science a French initiative that seeks to educate the public on scientific topics It’s time to take stock of the events held in the Ain department many of which involved CERN’s participation.  technical and industrial association of the Ain department officially opened the 31st edition of the Fête de la science in the main auditorium of Bourg-en-Bresse’s Scène nationale The evening kicked off with a screening of the documentary film Big Bang CERN’s former Director for Accelerators and Technology and astrophysicist Nicolas Laporte led a roundtable discussion on the theme of the infinitely big and the infinitely small which attracted an enthusiastic 350-strong audience.  more than 80 science enthusiasts came to the opening of the exhibition “Une mission scientifique pour le XXIe siècle” (A scientific mission for the twenty-first century) in Saint-Genis-Pouilly during which local youngsters enjoyed CERN’s science show See the Invisible The exhibition will be on display at the Médiathèque Georges Sand until the end of October Around a hundred pupils from the Lycée international in Saint-Genis-Pouilly also attended a screening of the film Francois Englert and got the chance to talk to its director and producer as well as to Belgian physicists Albert de Roeck and Filip Moortgat Lastly, on Saturday 15 October, CERN hosted a stand at the Fête de la science et de la biodiversité in Ferney-Voltaire, which provided the perfect opportunity to show our neighbours the efforts the Organization is making to limit its environmental footprint as much as possible. The main focus was CERN’s flagship heat recovery project at point 8 of the LHC which will heat a new neighbourhood being built in Ferney-Voltaire Visitors of all ages and from all backgrounds had the opportunity to find out about the various environmental themes presented and to learn more about the heat recovery project from CERN engineers Serge Claudet and Paul Pepinster We would like to extend our warm thanks to the events’ organisers and to the many volunteers who help to promote CERN’s activities in an engaging and accessible way.    Some say the trial is unethical. Others, that not doing it would be immoral Childhood exposure to a common gut bacterium could be responsible For now, the evidence for neuromodulation products is slim Many will still be culled under false pretences 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A a Novartis company and leader in nuclear medicine theragnostics today announced that it has entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical a leading radiopharmaceutical company in Japan to develop and commercialize radiolabeled FF-10158 for oncology indications AAA is granted worldwide rights to FF-10158 in exchange for an upfront payment and future milestones and royalties FF-10158 is a pre-clinical small molecule antagonist with high affinity for integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Integrins are cell surface receptors that are embedded in the cell membrane Integrin alphavbeta3/5 subtypes are over expressed on many types of cancer cells and the blocking of integrin signalling has been shown to inhibit tumor growth angiogenesis (formation of blood vessels) and metastasis1,2,3 AAA plans to develop a theragnostic pairing of compounds based on FF-10158 including a gallium 68-labeled drug for diagnosis and a lutetium 177-labeled drug for therapy “Our goal is to develop radiopharmaceuticals that transform oncology treatment,” said Susanne Schaffert “The in-licensing of FF-10158 expands our oncology theragnostic pipeline and we believe that this approach to integrating diagnostics and therapeutics has the potential to change patient management.” Among the first potential indications planned for investigation is glioblastoma an orphan disease with high unmet medical need Increased alphavbeta3 expression on glioblastoma is associated with invasive growth and poor survival4,5 Integrin-targeted delivery of radionuclides has been explored in pre-clinical models of glioblastoma6 FUJIFILM Toyama Chemical contributes to healthcare through the research and development manufacturing and distribution of radiopharmaceuticals as well as other kinds of therapeutic drugs in Japan The company is responsible for core elements of the healthcare business of FUJIFILM Corporation that seeks to expand its business in the areas of disease prevention FUJIFILM Toyama Chemical offers Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) diagnostics therapeutic radiopharmaceuticals and small molecule pharmaceutical products This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 Forward-looking statements can generally be identified by words such as “potential,” “goal,” “planned for investigation,” “will,” “plans,” “expect,” “believe,” “investigational,” “pipeline,” or similar terms or by express or implied discussions regarding potential marketing approvals new indications or labeling for the investigational or approved products described in this press release or regarding potential future revenues from such products or regarding potential outcomes and success of the exclusive option and license agreement with FUJIFILM Toyama Chemical You should not place undue reliance on these statements Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect actual results may vary materially from those set forth in the forward-looking statements There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market Neither can there be any guarantee that such products will be commercially successful in the future Nor can there be any guarantee that the exclusive option and license agreement with FUJIFILM Toyama Chemical will achieve any or all of its intended goals our expectations regarding such products and the exclusive option and license agreement with FUJIFILM Toyama Chemical could be affected by the uncertainties inherent in research and development including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety quality or manufacturing issues; potential or actual data security and data privacy breaches or disruptions of our information technology systems and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information About Advanced Accelerator Applications S.A A neuroendocrine tumour (NET) in the pancreatic islet cells one of the rarer forms of NET.Credit: OGphoto/ Getty Images Neuroendocrine tumours (NETs) begin in specialist cells at the intersection of the nervous and hormonal systems NETs can arise at many different locations across the body although two-thirds occur in the intestines (known as carcinoid tumours) NETs share commonalities based on the basal cell type affecting around 7 people per 100,000 in the United States each year1 Clinical research and therapeutic innovations have improved awareness diagnosis and treatment of NETs over the past 30 years — and particularly over the past decade these advances have been a community achievement Here are perspectives from key members of this NET community on the progress made when it comes to managing this form of cancer a gastroenterologist and clinician at Trinity College Dublin and St and past-chairperson of the European NET Society (ENETS) executive director of the International Neuroendocrine Cancer Alliance (INCA) Chief Commercial Officer for Advanced Accelerator Applications (AAA) Head of Communications and Patient Advocacy and past-chairperson of the European NET Society (ENETS)Credit: Dermot O’Toole Is society sufficiently educated and aware of NETs but specialists and primary care services will benefit from more education patient groups and industry can contribute to raising awareness and help improve health outcomes What are the most recent advancements in NET research These give more accurate information and help us to plan therapies more confidently for our patients we’ve seen treatment advances in disease management New drugs such as telotristat can treat carcinoid syndrome And the ‘centre of excellence’ model is improving the way NETs are managed at the country level diagnostic and therapeutic advances are increasing overall survival for the majority of NET patients executive director of the International Neuroendocrine Cancer Alliance (INCA)Credit: Teodora Kolarova and was one of its top downloaded papers 2018-2019 This survey inspired another global effort: SCAN (the Survey of Challenges in Access to Diagnostics and Treatment for NET Patients) SCAN examined the reasons for the gaps in diagnosis and care for NET patients around the world It was completed by 2,795 NET patients and healthcare professionals from 68 countries across 6 continents SCAN represents the largest compendium of data on management of NETs so far and its findings have been presented at all major conferences in 2020 How have you helped improve care and treatment of NETs we are involved in a number of initiatives to help patients access the best care possible such as EURACAN (the European Reference Network for Rare and Adult Cancers) and the European Cancer Organisation Code of Cancer Practice We are also active in a European political initiative to contribute to debates on how health-care systems can welcome innovative cancer therapies and also engage with policy-makers and EU institutions to overcome geographical variation in access to radioligand therapies since access is ultimately a country-based issue we are working to equip our member organizations around the world with evidence-based tools to advocate for optimal care for NET patients in their communities Working with governments and decision-makers is really crucial if we are to bring about meaningful policy change and improve the lives of those living with NETs has worked closely with the National Institute for Health and Care Excellence (NICE) on its health technology appraisals in other health technology assessment systems and are committed to continue to make a difference We are looking to strike more effective partnerships that can ensure access to equitable care worldwide based in Saint-Genis-Pouilly FranceCredit: Advanced Accelerator Applications It has been an absolute privilege for AAA to partner with the NET patient community We have so many passionate people from a range of backgrounds who are driven to make the lives of cancer patients better We are proud to continue Novartis’s legacy: they helped to form INCA and create patient awareness programmes and improve disease awareness for NETs Partnering with the NET patient community has been so important and our journey together in recent years has been incredibly rewarding like sharing best practice and pursuing more innovation in NET cancer treatment Doing this effectively requires deeper partnerships in the future This approach should be the norm across all cancers and beyond also at AAA.Credit: Advanced Accelerator Applications The future looks more promising for those living with NETs and we’re getting a better understanding of NETs through new research efforts is collecting information on diagnostic and therapeutic strategies and investigating the epidemiology of NET Tools like this mean we can improve multicentre and multinational collaborations and better understand the evolving therapeutic landscape for NETs There needs to be more shared data on sequencing of treatments and we want to see equitable access for NET patients around the world and future innovations must be rolled out for therapeutic use We need to see more research into immunotherapy for NET treatment as well as into the best combination of treatment approaches These data could bring personalized NET treatment based upon individual patient tumour biology the future has to be based on meaningful partnerships Patient advocacy groups have to be front and centre to ensure that the lives of people with NETs will genuinely improve day-by-day We have a new shared responsibility to make sure that all patients live better lives not necessarily those of Advanced Accelerator Applications Download references Today's print edition Home Delivery Scientists at Europe's physics research center are preparing to unwrap the biggest trove of data yet from the Large Hadron Collider (LHC) three years after they confirmed the existence of the elusive Higgs boson "In the life of accelerator physics there are few moments like the one we are living through," said Tiziano Camporesi leader of the CMS experiment at CERN.googletag.cmd.push(function() { googletag.display('div-gpt-ad-1499653692894-0'); }); "This is the time when the probability of finding something new is highest." In a time of both misinformation and too much information quality journalism is more crucial than ever.By subscribing Your subscription plan doesn't allow commenting. To learn more see our FAQ Sponsored contents planned and edited by JT Media Enterprise Division The twenty-two flags of the CERN Member States are fluttering again in front of the Meyrin site they were hoisted by scientists from each Member State during the inauguration ceremony of the Esplanade des Particules The flags are arranged in alphabetical order by the name of the country in French or Allemagne) closest to the Geneva city centre and and the last flag (Switzerland or Suisse) closest to Saint-Genis-Pouilly CERN’s official address is now “Esplanade des Particules 1” The Esplanade des Particules was constructed within the framework of the France-Vaud-Geneva conurbation project following an international urban planning competition It was financed by the Swiss Confederation thousands of visitors traversed the Esplanade on the occasion of Researchers’ Night shows and visits were offered to the curious minds The event was a great success: some 4000 people took part this year Around one hundred volunteers were there to enthusiastically answer their questions Pint of Science is an annual global science festival that gets researchers to share and discuss their findings with people in their local pub, bar, cafe or other public space. The first edition of Pint of Science took place in May 2013 in just three UK cities It quickly took off around the world and now happens in nearly 30 countries and over 400 cities For the first time, CERN is taking an active part in some of the many Pint of Science events that are being organised in neighbouring France and Switzerland We’ve planned three amazing nights for you to learn about CERN meet our scientists and have a drink with them you don't need any prior scientific experience just come and enjoy our scientists’ interactive presentations For more information and to register:  https://indico.cern.ch/e/pintofscience23 Registration is recommended for the event in Saint-Genis-Pouilly The CineGlobe festival was founded in 2007 and celebrates cinema inspired by science Its aim is to select the best new films and to bring film-makers together CineGlobe is returning for its 12th edition with four special events in Geneva and neighbouring France the spotlight will be on science and society “CineGlobe in Orbit” will consist of three satellite events organised in partnership with the towns of Grand-Saconnex It kicks off with an event in Grand Saconnex on 26 August Finally, the festival will come to a close by landing at CERN’s Science Gateway on 9 November for an event organised in collaboration with the artist collective Gruppe Laokoon and the Geneva International Film Festival (GIFF) festivalgoers will be treated to a must-see experimental play called Mauvais Je(ux) which will be performed as part of the official GIFF programme This innovative production explores the technologies that influence our society and each and every one of us using the digital data of a real but anonymous person Talented actors will bring to life four unique versions of “je” all based on the same data but seen from different perspectives CineGlobe has launched two calls for the play: For more information about the festival and to register for events, visit the official CineGlobe website: https://cineglobe.ch CERN announced one of the greatest scientific discoveries of the 21st century: the ATLAS and CMS experiments had finally found evidence of the existence of the elementary particle that had been more sought after than any other since the 1960s Peter Higgs and François Englert received the Nobel Prize in Physics CERN is celebrating the tenth anniversary of the discovery by organising a series of cinema and discussion evenings entitled Particle Fever continues .. is an intimate portrait of six brilliant scientists seeking to unravel the mysteries of the universe in the run-up to the discovery of the Higgs boson Each screening will be followed by a discussion with a group of CERN scientists How has the Higgs boson changed our understanding of the universe If these are questions you’re eager to hear answered come along for an enjoyable evening of lively debate!  Three events will take place in June, in Meyrin, Saint-Genis-Pouilly and Saint-Julien-en-Genevois. The highlight of the public celebrations will be an evening event at CERN’s Globe of Science and Innovation at 5.00 p.m. on Sunday, 3 July, which will round off the 11th CineGlobe science film festival Saint-Genis-Pouilly | Théâtre le Bordeau: Saturday Saint-Julien-en-Genevois | Ciné Rouge & Noir: Thursday CERN | Globe of Science and Innovation: Sunday Cycling between Meyrin and Prévessin just got better Since the new cycle path on the Route de l’Europe opened a few days ago cyclists can now get from one site to the other in complete safety cyclists from Prévessin can get to CERN or the tram terminus more easily from their commune in the presence of local politicians as well as CERN representatives.  the local authorities and also by funds from the CERN-Pays de Gex Consultation Committee are used to finance projects benefiting the public the path stops just before the traffic lights by the Prévessin site will be created in 2017.  Work is due to begin next spring Whether you’re on the path or on the road, don’t forget to wear a helmet and reflective clothing, and obey the rules of the road Now that the 2018 Bike to Work campaign has drawn to a close CERN can be proud of a record turnout of cyclists and we hope you’ll keep on cycling – safely – through the summer months joined by a large number of this year’s cohort of CERN summer students Although June passed off safely by and large there were nevertheless some avoidable accidents so here are some tips to help you reach your destination safely…